PALB2 was recently identified as a nuclear binding partner of BRCA2. Biallelic BRCA2 mutations cause Fanconi anemia subtype FA-D1 and predispose to childhood malignancies. We identified pathogenic mutations in PALB2 (also known as FANCN) in seven families affected with Fanconi anemia and cancer in early childhood, demonstrating that biallelic PALB2 mutations cause a new subtype of Fanconi anemia, FA-N, and, similar to biallelic BRCA2 mutations, confer a high risk of childhood cancer.
Subscribe to Journal
Get full journal access for 1 year
only $17.42 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Kutler, D.I. et al. Blood 101, 1249–1256 (2003).
Niedernhofer, L.J., Lalai, A.S. & Hoeijmakers, J.H.J. Cell 123, 1191–1198 (2005).
Taniguchi, T. & D'Andrea, A.D. Blood 107, 4223–4233 (2006).
Shivji, M.K. & Venkitaraman, A.R. DNA Repair (Amst.) 3, 835–843 (2004).
The Breast Cancer Linkage Consortium. J. Natl. Cancer Inst. 91, 1310–1316 (1999).
Howlett, N.G. et al. Science 297, 606–609 (2002).
Offit, K. et al. J. Natl. Cancer Inst. 95, 1548–1551 (2003).
Hirsch, B. et al. Blood 103, 2554–2559 (2004).
Wagner, J.E. et al. Blood 103, 3226–3229 (2004).
Reid, S. et al. J. Med. Genet. 42, 147–151 (2005).
Xia, B. et al. Mol. Cell 22, 719–729 (2006).
Lejeune, F. & Maquat, L.E. Curr. Opin. Cell Biol. 17, 309–315 (2005).
Godthelp, B.C. et al. Mutat. Res. 594, 39–48 (2006).
de Chadarevian, J.P., Vekemans, M. & Bernstein, M. Arch. Pathol. Lab. Med. 109, 367–369 (1985).
Chandra, S. et al. Mol. Ther. 12, 976–984 (2005).
We would like to thank all the families with Fanconi anemia for cooperating in this study and the many physicians that have referred families for participation in the research. In particular, we thank the doctors and counselors who provided samples and information from the FA-N cases, including R. Beier, T. Brenn, R.C. Lewandowski, M. Hamre, R.E. Harris, A. Carlson, V.M. Der Kaloustian, N. Wong and M. Buyukpamukcu. We thank B. Xia and D. Livingston for the PALB2 antibody and the pOZC-PALB2 vector; K. Spanova and S. Fielding for technical assistance with PALB2 sequencing; R. Friedl, B. Gottwald and S. Furlan for the flow cytometry analyses and handling of patients' cells and M. Stratton, A. Futreal and R. Scott for comments on the manuscript. We acknowledge use of controls from the British 1958 Birth Cohort DNA collection, funded by the Medical Research Council grant G0000934 and the Wellcome Trust grant 068545/Z/02. This work forms part of the UK Childrens' Cancer and Leukaemia Group's FACT (Factors Associated with Childhood Tumours) Study. The work was supported in part by the following: R37HL32987 and R01CA82678 from the US National Institutes of Health (A.D.A.); the Daniel Ayling Fanconi Anaemia Trust (C.G.M.); the Deutsche Fanconi-Anamie-Hilfe e V., Schroeder-Kurth-Fond and the Fanconi Anemia Research Fund (D.S., H.H.); the Deutsche Forschungsgemeinschaft and Elterninitiative Kinderkrebsklinik Duesseldorf e. V. (H.H.); the Jewish General Hospital Weekend to End Breast Cancer, Rethink Breast Cancer, Canada and Canadian Foundation for Innovation (M.T.); the Breast Cancer Campaign (P.K.) and, primarily, the Institute of Cancer Research and Cancer Research UK (S.R., S.H., K.B., S.S., N.R.).
The authors declare no competing financial interests.
About this article
Cite this article
Reid, S., Schindler, D., Hanenberg, H. et al. Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nat Genet 39, 162–164 (2007). https://doi.org/10.1038/ng1947
Hereditary Cancer in Clinical Practice (2021)
Trends in Cancer (2021)
The p.Ser64Leu and p.Pro104Leu missense variants of PALB2 identified in familial pancreatic cancer patients compromise the DNA damage response
Human Mutation (2021)
International Journal of Cancer (2021)